New-variant Creutzfeld-Jakob disease and leucocyte depletion of blood components

Infusionstherapie und Transfusionsmedizin

Volumn 26, Issue SUPPL. 2, 1999, Pages 24-30

  Williamson, L M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Leucocyte depletion; New variant Creutzfeld Jakob disease

Indexed keywords

PRION PROTEIN;

BLOOD TRANSFUSION; CELL SEPARATION; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; HUMAN; INFECTION PREVENTION; INFECTION RISK; PRION; VIRUS TRANSMISSION;

EID: 0032715163     PISSN: 10198466     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053535     Document Type: Conference Paper

References (20)

1. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347:921-925.
2. Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J: The same prion strain causes vCJD and BSE. Nature 1997;389:448-450.
3. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttle A, McCardle L, Chree A, Hope J, Birkett C, Fraser H, Bostock CJ: Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997;389: 498-501.
4. Dodelet VC, Cashman NR: Prion protein expression in human leukocyte differentiation. Blood 1998;91:1556-1561.
5. 27-30 is a normal soluble prion protein fragment released by human platelets. Biochem Biophys Res Commun 1996;223:572-577.
6. Perini F, Frangione B, Prelli F: Prion protein released by platelets. Lancet 1996;347:1635-1636.
7. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rosser MN, Thomas DJ, Frosh A, Tolley N, Bell JE, Spencer M, King A, AI-Sarraj S, Ironside JW, Lantos PL, Collinge J: Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353:183-189.
8. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN: The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998;38: 810-816.
9. Klein MA, Frigg R, Flechsig E, Kalinke U, Bluethmann H, Bootz F, Suter M, Zinkernagel RM, Aguzzi A: A crucial role for B cells in neuroinvasive scrapie. Nature 1997;390:687-690.
10. Klein M, Frigg R, Raeber AJ, Flechsig E, Hegyi I, Zinkernagel RM, Weissman C, Aguzzi A: PrP expression in B-lymphocytes is not required for prion neuroinvasion. Nat Med 1998;4:1429-1433.
11. Assessment of the Risk of Exposure to vCJD Infectivity in Blood and Blood Products. Final Report. Department of Health/Det Norske Veritas, February 1999.
12. Council of Europe: Guide to the Preparation, Use and Quality Assurance of Blood Components, ed 5. Strasbourg, Council of Europe Publishing, 1999.
13. British Committee for Standards in Haematology, Blood Transfusion Task Force (Chairman A Napier): Guidelines on the clinical use of leucocyte-depleted blood components. Transfus Med 1998;8:59-71.
14. Dumont U, Dzik WH, Rebulla P, Brandwein H, and the members of the BEST Working Party of the ISBT: Practical guidelines for process validation and process control of white cell-reduced blood components: Report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Transfusion 1996;36:11-20.
15. Adams MR, Johnson DK, Busch MP, Schembri CT, Hartz TP, Heaton WA: Automatic volumetric capillary cytometry for counting white cells in white cell-reduced plateletpheresis components. Transfusion 1997;37:29-37.
16. Shiba M, Tadokoro K, Sawanobori M, Nakajima K, Suzuki K, Juji T: Activation of the contract system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received the filtered platelets. Transfusion 1997;37:457-462.
17. SHOT Office: Serious Hazards of Transfusion Annual Report 1997-1998. Manchester, Manchester Blood Centre, 1999.
18. Pamphilon DH, Rider JR, Barbara JAJ, Williamson LM: Prevention of transfusion-transmitted cytomegalovirus infection. Transfus Med 1999;9:115-123.
19. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-3603.
20. Tartter PI, Mohandas K, Azar P, Endres J, Kaplan J, Spivack M: Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998;176:462-466.